title: Classical Kaposi sarcoma: prognostic factor analysis of 248 patients.
abstract: BACKGROUND
  Classical Kaposi sarcoma (CKS) is a rare indolent neoplasm that is particularly prevalent among Jews of Ashkenazi and Mediterranean origin. Data regarding prognostic factors for CKS are scarce. The aim of the current retrospective analysis was to better define prognostic subgroups among patients with CKS.
  
  
  METHODS
  Between 1960 and 1995, 248 consecutive patients with CKS were treated at the Rambam and Rabin Medical Centers in Israel. Although treatment options included local excision, radiotherapy, and chemotherapy, observation alone was used for 31% of patients. For prognostic factor analysis, disease progression was classified as any progression and dissemination, and progression-free survival was calculated for each.
  
  
  RESULTS
  At a median follow-up of 20 months, four patients (1.6%) died of CKS. Of the patients eligible for analysis, 94 of 220 (39%) had any progression and 23 of 120 (18%) had dissemination. Only 8 of 202 (4%) had visceral spread. On univariate analysis, age was a statistically significant prognostic factor for any progression (P = 0.04), whereas immunosuppression and visceral involvement at presentation had only borderline significance. Immunosuppression was the only prognostic factor for dissemination (P = 0.003). On multivariate analysis, both age and immunosuppression were significant prognostic factors for any progression (P = 0.001 and 0.01, respectively). Immunosuppression was also predictive of dissemination (P = 0.006).
  
  
  CONCLUSIONS
  Immunosuppression and older age (50 years and older) are strongly associated with poorer outcome among CKS patients. The two end points used in this study may be used for future prognostic factor analyses.
authors.affiliation: Institute of Oncology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel. brennerb@mskcc.org
authors.forename: Baruch
authors.initials: B
authors.lastname: Brenner
authors.forename: Alina
authors.initials: A
authors.lastname: Weissmann-Brenner
authors.forename: Erica
authors.initials: E
authors.lastname: Rakowsky
authors.forename: Sara
authors.initials: S
authors.lastname: Weltfriend
authors.forename: Eyal
authors.initials: E
authors.lastname: Fenig
authors.forename: Rachel
authors.initials: R
authors.lastname: Friedman-Birnbaum
authors.forename: Aaron
authors.initials: A
authors.lastname: Sulkes
authors.forename: Shai
authors.initials: S
authors.lastname: Linn
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000276:immunology / Q000401:mortality / Q000556:secondary / Q000628:therapy; D015996:Survival Rate